Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
This study will serve as a component of a larger program investigating the benefits of stereotactic radiotherapy in patients with metastatic disease.
This particular study will serve as a benchmark analysis.
All patients will receive stereotactic radiotherapy directed at metastatic tumors.
If primary prostate cancer is active and has not previously been treated with radiation therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended. The metastatic tumor will be treated at the same time.
Hormone therapy will be recommended for all patients.
Patients will be asked to complete questionnaires at regular intervals.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic cancer of the prostate,
Patients may have received prior surgery,
Prior radiation therapy, androgen deprivation therapy (ADT), immunotherapy, bone metastasis directed therapy, or chemotherapy for prostate cancer.
You may not be if
End-stage heart disease,
End-stage liver disease,
End-stage renal disease,
End stage pulmonary disease
Current brain or central nervous system metastasis.
